VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

Yes, not sure why as they just raised enough money to start the phase 2 injunctive. Top people in depression field working on this.

Rumors are AGN stopped the trials on the oral application and are sticking with intravenous delivery but that does not effect VTGN. It is good for VTGN in the long run.

Can just tell you 2 recent ones we had, Salix dropped 50 percent and was bought out and AERI dropped from 33 to 8 and recently hit 60. Sarepta is another one we bought on a crash, as well as BMY.

Vtgn is less than 14 months away from phase 2 adjunctive results, I think they are holding off until January to start trial. In January the NIH phase 2a results could be out...

No guarantees here but it is very unusual to have a potential 2 to 4 billion dollar drug at these prices considering there has not been any negative results.